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Background: The objective of this study was to explore the cycle-to-cycle reproducibility of serum progesterone
level and progesterone/estradiol (P/E2) ratio in the final step of triggering oocyte maturation in patients undergoing
repeated consecutive controlled ovarian hyperstimulation for in vitro fertilization (COH-IVF) treatment and to investigate
the clinical parameters associated with serum progesterone concentration and P/E2 ratio.
Methods: We retrospectively studied 524 cycles in 203 infertile women who underwent two or more fresh COH-IVF
cycles from July 1998 to May 2012 in a university hospital IVF unit. The patients were divided into groups according to
the number (2, 3 or > = 4) of total successive IVF cycles with successful oocyte retrieval. The within-subject reproducibility
of serum P and P/E2 was tested by calculating intra-class correlation coefficients (ICCs). Multiple linear regression analysis
was used to assess the association between patient variables and pre-ovulatory serum P level and P/E2 ratio.
Results: The ICCs in women who underwent 2, 3 and > = 4 IVF cycles were −0.052, 0.163 and 0.212, respectively, for
serum P concentration and 0.180, 0.168 and 0.148, respectively, for P/E2 ratio. All ICCs for both serum P and P/E2 ratio
were indicative of poor reproducibility. The number of oocytes was significantly positively related to P concentration, and
endometrial thickness was significantly negatively related to P concentration and P/E2 ratio.
Conclusion: The cycle-to-cycle reproducibility of pre-ovulatory serum P concentration and P/E2 ratio was poor in individual
patients, and these fluctuations were more cycle- than patient-dependent. The number of oocytes was the most significant
factor relating to P concentration. By using milder stimulation approach to produce fewer oocytes in the next cycle is a
strategy to overcome the high serum P concentration, while clinicians should consider each patient’s general condition
including the age, ovarian reserve, embryo grading and the capacity of frozen-thawed embryo transfer.
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It is well known that gonadotropin-releasing hormone
(GnRH) agonists and antagonists, known as GnRH ana-
logues, can effectively eradicate the premature luteinizing
hormone surge, and they are almost routinely used during
controlled ovarian hyperstimulation (COH) in modern
in vitro fertilization (IVF) treatment. However, unpre-
dicted elevation of serum progesterone without an in-
crease luteinizing hormone (LH) in the late follicular
phase still occurs in patients co-treated with GnRH-a and
COH, a phenomenon called premature progesterone rise
(PPR) [1]. The reported incidence of PPR varies greatly
from 3 % to 71 %, and it has been reported to be as high
as 35 % in GnRH agonist cycles and 38 % in antagonist cy-
cles [2–5]. PPR has previously been defined based on ab-
solute progesterone concentration or as a progesterone/
estradiol (P/E2) ratio on the day of human chorionic
gonadotropin (hCG) administration [6–8]. The effects
of elevated serum progesterone on oocyte maturation,
endometrial development and receptivity, and prognostic
outcomes after embryo transfer are controversial. An in-
creasing number of retrospective studies suggest that pro-
gesterone elevation on the day of hCG administration
may have a negative effect on pregnancy rate, and this hy-
pothesis was confirmed by a meta-analysis based on the
analysis of 60,000 IVF cycles [9–11]. However, PPR re-
mains a controversial issue because several studies did not
find this association [6, 12, 13]. In addition, whether the
level of serum progesterone in consecutive cycles remains
constant or fluctuates in an individual undergoing re-
peated COH-IVF treatment is unknown.
In this study, we aimed to explore the inter-cycle repro-
ducibility of serum progesterone and P/E2 ratio in the final
step of triggering oocyte maturation in patients undergo-
ing repeated consecutive COH-IVF treatment. The associ-
ation of both serum progesterone concentration and P/E2
ratio, and the patient’s clinical characteristics and ovarian
stimulation responses were also assessed.
Methods
Subjects
This retrospective, single-center cohort study involved
consecutive infertile couples who underwent two or more
fresh IVF and/or intracytoplasmic sperm injection-
embryo transfer (ICSI-ET) cycles from July 1998 to May
2012 in our IVF unit. Women older than 45 years of age
and those with intervals of more than 5 years from the
first to the last IVF cycle were excluded. The patients were
divided into groups according to the number (2, 3 or ≥ 4)
of total successive IVF cycles with successful oocyte re-
trieval. The patients’ characteristics included age, body
mass index, basal follicle-stimulating hormone (FSH),
luteinizing hormone, estradiol levels on cycle day 3, and
causes of infertility. The study was approved by theInstitutional Review Board of the Ethics Committee of
Chang Gung Medical Foundation, Taiwan in March 2014
(CGMF IRB No.: 103-1156B).Ovarian stimulation protocols
All women received a GnRH-a long protocol, a GnRH-a
short protocol or a GnRH antagonist protocol depend-
ing on ovarian reserve, which was assessed by the pa-
tient’s age, baseline serum FSH concentration, previous
ovarian response to gonadotropins, and the preference
of each clinician. The initial dose of gonadotropin was
individualized (varied from 75 to 450 IU) for each pa-
tient using either human menopausal gonadotropin
(hMG) or FSH (purified or recombinant), with further
dose adjustments based on each patient’s ovarian re-
sponse as assessed by serum estradiol concentration and
sonographic monitoring of follicular growth. In the
GnRH antagonist protocol, 0.25 mg of cetrorelix acetate
(Cetrotide®; Serono, Baxter Oncology GmbH, Halle,
Germany) was administered daily starting on day 6 of
ovarian stimulation or when the lead follicle reached ≥
14 mm in diameter; administration continued until the
day of hCG injection. When the lead follicle reached
16–18 mm in diameter, hMG and FSH were discontin-
ued, and hCG (Ovidrel®; Serono, Modugno, Italy) was
administered. Oocyte retrieval was scheduled 36–38 h
later. Standard IVF or ICSI procedures, depending on
semen parameters, were used to achieve oocyte
fertilization, as previously described [14, 15].
On day 3, all embryos were graded on a scale of 0 to
4, which was based on a modification of Veeck's mor-
phological grading system and our previous report [16,
17]. Embryo transfer was performed 3 to 5 days after
oocyte retrieval, and no more than 4 embryos were
transferred per cycle. During the luteal phase, each pa-
tient received 800 mg/day of micronized progesterone
(Utrogestan; Piette International Laboratories, Brussels,
Belgium) intravaginally or 90 mg of progesterone vagi-
nal gel once daily (Crinone 8 %; Serono Pharmaceuticals
Ltd., UK) starting on the day after oocyte retrieval. Clin-
ical pregnancy was defined as one or more gestational
sacs detected by transvaginal ultrasound.Hormone measurements
Serum P and E2 were measured on the day of hCG ad-
ministration of each IVF cycle using a commercially
available immunoassay system (ADVIA Centaur ® XP,
Siemens, USA). The lower limits of detection were
0.15 ng/mL for P and 11.8 pg/mL for E2. The intra- and
inter-assay coefficients of variation were 5.2 % and
3.5 %, respectively, for P and 5.0 % and 4.1 %, respect-
ively, for E2. The P/E2 ratio was calculated as P (ng/mL)
x 1,000/E2 (pg/mL).
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All statistical analyses were performed using SPSS (ver.
17.0; Statistical Package for Social Sciences, Inc., Chicago,
IL, USA). Continuous data are reported as the mean ±
standard deviation and compared in the three groups by
one—way analysis of variance (ANOVA), whereas categor-
ical variables were compared by the χ2 or Fisher’s exact
tests. Fisher’s least significant difference post hoc test was
applied when ANOVA revealed statistical significance. To
assess the central tendency and distribution of the mea-
surements, we visualized pre-ovulatory serum P concen-
trations and P/E2 ratios per cycle within the same patient
using box plots. The within—subject reproducibility of
serum P and P/E2 was estimated by calculating intra-class
correlation coefficients (ICCs) and their 95 % confidence
intervals [18]. ICCs were defined as the ratio of between-
subject variability to total variability, the latter including
between—and within-subject variability. ICC values ≥ 0.75,
between 0.60 and 0.74, between 0.40 and 0.59 and < 0.40
or a negative value were interpreted as excellent, good,
fair, and poor, respectively [19, 20]. Multiple linear regres-
sion analysis was used to assess the association between
patient variables and pre-ovulatory serum P level or P/E2
ratio. All P values were two-sided, and a P value of less
than 0.05 was considered to be statistically significant.
Results
A total of 524 fresh IVF cycles in 203 infertile women were
included in the analysis, and the mean interval from the
first to the last IVF cycle was 19.1 ± 15.5 months. Of these
203 women, 125 (61.5 %) underwent two fresh IVF cycles,
52 (25.6 %) underwent three cycles, and 26 (12.8 %) under-
went four to seven IVF cycles. The patient baseline demo-
graphic, cycle characteristics and cycle outcomes of the
three groups are summarized in Table 1.
The mean serum P concentration and P/E2 ratio on the
day of hCG administration were 1.62 ng/mL and 1.11, re-
spectively. As expected, the women who had more IVF
treatment cycles tended to be older and had longer inter-
vals between IVF treatments, particularly for patients who
underwent ≥ 4 IVF cycles. In addition, the main IVF proto-
col also changed, from the GnRHa long protocol to the
short and antagonist protocols. There were no differences
among the three groups in body mass index, method of
assisted reproductive technology (ART), duration of ovarian
stimulation and normal fertilization rate. Interestingly, the
pre-ovulatory serum P concentration was significantly
lower among patients who underwent more IVF cycles,
while the P/E2 ratio was similar among the three groups.
Peak E2 concentrations, number of follicles ≥ 16 mm in
diameter, and the number of oocytes retrieved were higher
among women who underwent 2 or 3 IVF cycles than
among those who underwent ≥ 4 cycles. In contrast,
women who underwent ≥ 4 IVF cycles required a higherdose of gonadotropin but had fewer follicles than women
who underwent 2 or 3 IVF cycles. In addition, fewer oo-
cytes were collected, the endometrium was thinner, and the
mean embryo score per embryo was lower in women who
underwent ≥ 4 IVF cycles. These women also had lower
rates of implantation, clinical pregnancy and live birth des-
pite an equal number of embryos being transferred.
The distributions of serum P concentration and P/E2 ra-
tio on the day of hCG administration across 2 ~ 4 consecu-
tive IVF cycles are depicted in Fig. 1. The median serum P
concentrations in the 125 women who underwent 2 IVF cy-
cles each were 1.61 ng/mL in the first cycle and 1.64 ng/mL
in the second cycle, and the median P/E2 ratios were 0.76
and 0.83, respectively. In the 52 patients who underwent 3
IVF cycles, the median serum P concentration ranged from
1.39 to 1.58 ng/mL, and the median P/E2 ratio ranged from
0.70 to 0.80, with both showing similar distribution patterns
in each cycle. However, the box plots of the patients who
underwent 4 IVF cycles showed markedly different distribu-
tions across individual cycles.
The ICC data are summarized in Table 2. The ICCs
among women who underwent 2, 3, and ≥ 4 IVF cycles
were −0.052, 0.163 and 0.212, respectively, for serum P
concentration and 0.180, 0.168 and 0.148, respectively, for
P/E2 ratio. All of these ICCs were indicative of poor
reproducibility.
Multiple linear regression analysis showed that after
adjusting for possible confounders, serum P concentration
was positively correlated with E2 concentration (P = 0.009)
and the number of oocytes retrieved (P < 0.001) and nega-
tively correlated with endometrial thickness (P = 0.043)
(Table 3). Additionally, after adjusting for possible con-
founders, the P/E2 ratio was positively correlated with dur-
ation of stimulation (P < 0.001) and negatively correlated
with the number of oocytes retrieved (P = 0.002) and
endometrial thickness (P = 0.012) (Table 4).
Discussion
To the best of our knowledge, this study is the first to
assess the inter-cycle reproducibility of pre-ovulatory
serum P measurements and P/E2 ratio in individual
women who underwent multiple IVF/ICSI cycles. Our
major finding is that the cycle-to-cycle reproducibility
of both parameters was poor in individual patients.
These inter-cycle variations during repeated IVF cycles
suggest that neither serum P concentration nor P/E2 ra-
tio in a subsequent IVF cycle can be predicted from the
results in a previous cycle. Factors significantly associated
with serum P concentration included E2 concentration on
the day of hCG administration, the number of oocytes col-
lected and the thickness of the endometrium; factors signifi-
cantly associated with the P/E2 ratio included the duration
of stimulation, the number of oocytes retrieved and the
thickness of the endometrium.
Table 1 Patient baseline demographics, cycle characteristics and cycle outcomes of the three groups according to the number of
total in vitro fertilization cycles
Variable Overall 2 cycles 3 cycles ≥ 4 cycles P value
Baseline demographics
No. of cases (cycles) 203 (524 cycles) 125 (250 cycles) 52 (156 cycles) 26 (118 cycles)
Age (years) 34.3 ± 4.7 33.7 ± 4.4 a 33.7 ± 4.9 b 36.3 ± 4.4 ab < 0.001
Mean interval from 1st to last IVF cycle (months) 19.1 ± 15.5 14.2 ± 14.2 ab 24.7 ± 13.5 a 31.3 ± 15.0 b < 0.001
BMI (kg/m2) 21.5 ± 2.8 21.7 ± 3.1 21.2 ± 2.3 21.5 ± 2.7 0.220
Infertility factors 0.003
Male factor 194 (34 %) 86 (33 %) 58 (35 %) 50 (38 %)
Tubal factor 119 (21 %) 59 (22 %) 42 (25 %) 18 (14 %)
Ovulatory factor 75 (13 %) 37 (14 %) 15 (9 %) 23 (18 %)
Endometriosis factor 87 (15 %) 32 (12 %) 37 (22 %) 18 (14 %)
Unexplained factor 89 (16 %) 51 (19 %) 16 (9 %) 22 (17 %)
Cycle characteristics
IVF protocol < 0.001
GnRHa long protocol 351 (67 %) 179 (72 %) 116 (74 %) 56 (48 %)
GnRHa short protocol 130 (25 %) 48 (19 %) 31 (20 %) 51 (43 %)
Antagonist protocol 38 (7 %) 22 (9 %) 6 (4 %) 10 (9 %)
ART method (n) 0.132
Conventional IVF 336 (64 %) 171 (68 %) 92 (59 %) 73 (62 %)
ICSI 188 (36 %) 79 (32 %) 64 (41 %) 45 (38 %)
Duration of stimulation (days) 9.3 ± 1.8 9.4 ± 1.8 9.1 ± 1.7 9.4 ± 2.0 0.379
No. of gonadotrophin ampoules used 34.6 ± 14.5 32.5 ± 11.8 a 33.3 ± 13.7 b 40.8 ± 18.8 ab < 0.001
Estradiol (pg/mL) on hCG day 2177.3 ± 1441 2377.4 ± 1541 a 2360.5 ± 1443 b 1505.4 ± 938 ab < 0.001
No. of follicles≥ 16 mm on hCG day 4.91 ± 3.1 5.25 ± 3.1 a 5.23 ± 3.4 b 3.77 ± 2.4 ab < 0.001
Number of oocytes retrieved 6.9 ± 3.9 7.7 ± 4.0 a 7.2 ± 3.9 b 5.0 ± 3.1 ab < 0.001
EM (mm) on hCG day 13.0 ± 3.1 13.0 ± 3.0 a 13.5 ± 3.5 b 12.3 ± 2.5 ab 0.011
Pre-ovulation serum progesterone (ng/mL) 1.62 ± 0.6 1.72 ± 0.6 a 1.62 ± 0.7 b 1.41 ± 0.6 ab < 0.001
P/E2 ratio 1.11 ± 1.2 1.13 ± 1.3 1.02 ± 1.1 1.19 ± 0.7 0.557
Cycle outcomes
Normal fertilization rate (%) 77.4 (2830/3655) 77.1 (1488/1928) 76.2 (865/1134) 80.4 (477/593) 0.778
Mean no. of embryos transferred 2.5 ± 1.0 2.5 ± 1.0 2.5 ± 1.1 2.3 ± 1.1 0.106
Mean embryo score per embryo (Day 3) 3.3 ± 1.0 3.4 ± 0.9 a 3.3 ± 0.9 b 3.0 ± 1.2 ab 0.001
Implantation rate (%) 15.8 (208/1316) 18.7 (120/642) a 16.0 (64/399) b 8.7 (24/275) ab 0.004
Clinical pregnancy rate / transfer cycle (%) 33.7 (164/486) 40.0 (94/235) a 34.2 (50/146) b 19.0 (20/105) ab 0.022
Live birth rate / transfer cycle (%) 19.3 (94/486) 25.1 (59/235) a 18.4 (27/146) b 7.6 (8/105) ab 0.006
Note: Values are mean ± SD or proportion. Figures sharing the same superscript (a, b) are statistically significantly different at P < 0.05 by LSD analysis post hoc
No, number; IVF, in vitro fertilization; BMI, body mass index; ART, assisted reproductive technology; ICSI, intracytoplasmic sperm injection; hCG, human chorionic
gonadotropin; EM, endometrial thickness; P/E2, progesterone/estradiol
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cess number of mature follicles, each of which produces
a normal amount of P during the late follicular phase of
COH [9, 12, 21]. We found that pre-ovulatory serum P
concentrations were significantly higher among women
who underwent 2 or 3 cycles than among those who
underwent ≥ 4 IVF cycles. In addition, the peak E2 con-
centration was higher and more oocytes were collectedin those who underwent 2 or 3 cycles than in those who
underwent ≥ 4 IVF cycles. Multiple regression analysis
showed that serum P concentration was positively corre-
lated with both the number of oocytes retrieved and the
peak E2 level, which is consistent with the results of pre-
vious studies and with the above hypothesis [9, 11].
Thus, it is an option to overcome PPR by using milder
stimulation approach to produce fewer oocytes in the
Fig. 1 Box and whiskers plots depicting distribution of pre-ovulatory serum progesterone concentration and P/E2 ratio on the day of hCG administration
across 2 ~ 4 IVF cycles in each group of patients
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tient’s general condition including the age, ovarian reserve,
embryo grading and the capacity of frozen-thawed embryo
transfer.
We also observed a negative correlation between
serum P concentration and endometrial thickness,
which may indicate advanced endometrial maturation.
Advanced maturation of the endometrium, which has
been reported during the peri—and post-ovulatory
periods of the stimulation cycle [22–24], may be due to
several factors, including supra-normal estradiol con-
centration, early and increased exposure of the endo-
metrium to P and to hCG injections [25–28]. Other
studies have implied that endometrial thickness and
pattern may be useful indicators of endometrial recep-
tivity, and they have shown that a premature secretory
endometrial pattern is introduced by elevation of P. Ad-
vanced endometrial maturation may be unfavorable forimplantation and have an adverse effect on pregnancy
rates [29–32].
In this study, we retrospective analysis of a subgroup
of patients who had undergone repeated IVF/ICSI cycles
measured pre-ovulatory serum P concentration and P/E2
ratio over multiple IVF cycles in individual patients.
Women who had undergone ≥ 4 IVF cycles showed rela-
tively poor responder trend, which may be related to
aging. Older women have poorer ovarian responses and
yield fewer good quality embryos and fewer available
embryos to be frozen than younger women. Increasing
the number of attempted IVF cycles can result in a
higher cumulative pregnancy rate. However, while IVF
may largely overcome infertility in younger women, it
does not reverse the age-dependent decline in fertility,
especially in women aged ≥ 40 years [33]. Our findings
suggest that a maximum of 4 treatment cycles may
present a critical point in IVF because of the extremely
Table 2 Intraclass correlation coefficients of pre-ovulatory serum progesterone concentration and P/E2 ratio in patients who
underwent repeated consecutive in vitro fertilization cycles
Intraclass correlation coefficient (ICC)
2 cycles 3 cycles ≥ 4 cycles
Number of patients (cycles) 125 (250 cycles) 52 (156 cycles) 26 (118 cycles)
Pre-ovulatory serum P on hCG day (95 % CI) −0.052 (−0.24 ~ 0.14) 0.163 (−0.01 ~ 0.37) 0.212 (0.00 ~ 0.52)
P/E2 ratio on hCG day (95 % CI) 0.180 (−0.01 ~ 0.36) 0.168 (−0.13 ~ 3.77) 0.148 (−0.06 ~ 0.46)
CI, confidence interval
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curring subsequently.
The relationship between PPR and pregnancy outcome
remains the subject of much debate, and some studies
have hypothesized that the possible detrimental effect of
PPR is mainly through a negative impact on endometrial
development at the end of the follicular phase rather
than by negatively affecting embryo quality. This may re-
sult in embryo-endometrial asynchrony with poor endo-
metrial receptivity [10, 34, 35], and this may reduce
embryo implantation and pregnancy rates [24, 25]. Thus,
freezing embryos and transferring them in a subsequent
frozen-thawed cycle may avoid impairments in endomet-
rial receptivity, which is why it is the method most fre-
quently used to manage PPR.
The results of an oocyte donation program yielded
similar observations as the present study. In that study,
among 120 women who each donated oocytes on two
occasions, the serum P level was ≥ 1.2 ng/mL in the first
donation cycle but < 1.2 ng/mL (no further serum P ele-
vation) in the second cycle. The study also reported that
PPR did not have a negative impact on pregnancy rate
[34]. Notably, these results provide additional evidence
supporting inter-cycle variations in pre-ovulatory serum
P concentration among women undergoing repeated oo-
cyte donation IVF cycles.
No general consensus has been reached on the cut-off
value for PPR. Studies designed to determine the mostTable 3 Summary of multiple linear regression analysis for
parameters associated with pre-ovulatory serum progesterone
Parameter B SE (B) β Sig.(p)
Age (years) −0.010 0.007 −0.022 0.677
Body mass index (kg/m2) 0.000 0.011 −0.003 0.955
Number of gonadotropin
ampoules used
0.003 0.003 0.076 0.234
Duration of stimulation (day) 0.025 0.021 0.069 0.244
Estradiol (pg/mL) on hCG day 6.995E-5 0.000 0.152 0.009
Number of oocytes retrieved 0.039 0.010 0.235 < 0.001
Endometrium thickness (mm) −0.021 0.010 −0.098 0.043
R2 0.111
F 7.208*
* P < 0.001appropriate cut-off value have utilized receiver operating
characteristic (ROC) analysis, trend analysis or arbitrary
methods. In addition to pre-ovulatory serum P concentra-
tion, some studies have used P/E2 ratio to diagnose PPR,
however, the optimal cut-off value for P/E2 ratio has been
reported to range from 0.55 to 1.2 and P/E2 ratio has not
been shown to definitively predict IVF outcomes [6–8,
36]. We have previously presented data suggesting that
progesterone concentration is not the only factor deter-
mining the clinical pregnancy and live birth rates, and we
have found that PPR has an obvious negative impact on
pregnancy outcome only at extremely high progesterone
concentration (P ≥ 1.94 ng/mL) [37].
There were considerable inter-cycle variations in
serum P concentration and P/E2 ratio on the day of hCG
administration in the current study; the changes were bi-
directional and went either down or up. Further ques-
tions, such as whether women who always have constant
“normal” pre-ovulatory serum P levels in repeated IVF
cycles have better pregnancy outcomes, remain unre-
solved. Our study did not assess the recurrence of PPR.
The design of the study had several potential biases,
such as three different stimulation protocols used and
different types of gonadotropin preparations for ovarian
stimulation, which may mask the possible effect on
serum P concentration and the cycle outcome. Another
limitation is the small number of patients undergoing re-
peated IVF cycles. Further studies are required to answer
the unsolved questions mentioned above, investigate theTable 4 Summary of multiple linear regression analyses for
parameters associated with P/E2 ratio
Parameter B SE (B) β Sig.(p)
Age (years) 0.003 0.014 0.012 0.818
Body mass index (kg/m2) 0.023 0.020 0.055 0.256
Number of gonadotrophin
ampoules used
−0.009 0.005 −0.106 0.099
Duration of stimulation (day) 0.156 0.039 0.238 < 0.001
Number of oocytes retrieved −0.051 0.016 −0.166 0.002
Endometrium thickness (mm) −0.049 0.019 −0.123 0.012
R2 0.086
F 6.396*
* P < 0.001
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bility and potential clinical meaning of these parameters.
Conclusions
Cycle-to-cycle reproducibility of pre-ovulatory serum P
concentrations and P/E2 ratio was poor in individual pa-
tients, and the fluctuations were more cycle- than patient-
dependent. The number of oocytes was the most significant
factor relating to the P concentration. By using milder
stimulation approach to produce fewer oocytes in the next
cycle is a strategy to overcome PPR, while clinicians should
consider each patient’s general condition including the age,
ovarian reserve, embryo grading and the capacity of frozen-
thawed embryo transfer.
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